Metastatic breast cancer: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• HER2 193
• CDK4/6 49
• PIK3CA 24
• ESR1 11
• PD-L1 10
• BRCA1 2
• PI3K 13
• PARP 7
• BRCA2 2
• AKT 4
• PD-1 10
• STAT3 0
• PTEN 2
• TP53 0
• mTOR 5
• TROP2 4
• STING 0
• VEGF 4
• YAP 0
• PALB2 3
• MMP-9 0
• AR 0
• CXCR4 1
• EGFR 3
• HER3 4
• AMPK 0
• HDAC 1
• JAK 1
• CTNNB1 0
• FGFR 1
• PSMA 0
• ATM 0
• CD40 1
• EZH2 0
• FAK 0
• HIF-1 0
• MUC1 3
• PPAR 0
• BCL-2 1
• CD47 1
• COX-2 0
• ERK 0
• HSP90 0
• IGF1R 0
• IL-6 0
• MDM2 2
• MET 0
• MYC 0
• TNF 0
• B7-H3 1
• CCR5 0
• CSF1R 0
• CTLA-4 1
• JNK 0
• LAG-3 0
• MAPK 0
• NF1 0
• NRF2 0
• RANKL 0
• TIGIT 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 33+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

  NCT05807126· National Cancer Institute (NCI)· Updated 2 May 2024

  “No subjects enrolled in the study”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

  NCT04550494· National Cancer Institute (NCI)· Source

• Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.

  NCT04039230· Massachusetts General Hospital· Source

• Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

  NCT03990896· Massachusetts General Hospital· Source

• Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

  NCT02000622· AstraZeneca· Source

• Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer

  NCT06201234· GBG Forschungs GmbH· Source

• Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

  NCT00516724· AstraZeneca· Source

• A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

  NCT02163694· AbbVie· Source

• Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

  NCT05807126· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 19
• Organoids 7
• CRISPR-Cas Systems 4
• Gene Expression Profiling 62
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 3
• Exome Sequencing 5
• Proteomics 16
• Metabolomics 3
• Mass Spectrometry 1
• Flow Cytometry 9
• Immunohistochemistry 69
• Liquid Biopsy 19
• Circulating Tumor DNA 46
• Xenograft Model Antitumor Assays 109
• Positron-Emission Tomography 13
• Magnetic Resonance Imaging 64
• Machine Learning 30
• Deep Learning 23
• Cohort Studies 57
• Genome-Wide Association Study 1

• Impact of Transfer Learning and Model Capacity on Patch-Level Metastasis Detection Across Training Data Regimes.

  Stud Health Technol Inform, Sept 2026

• A multimodal cross-temporal fusion system for complementary evaluation of neoadjuvant chemotherapy in breast cancer.

  Eur J Radiol, Sept 2026

• Deep-learning-enabled multi-omics analyses for prediction of future metastasis in cancer.

  Nat Commun, Aug 2026

• Integrating MRI radiomics and deep learning for predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer: a multicenter study.

  BMC Med Imaging, Jul 2026

• A Multimodal Multitask Deep Learning Model Based on Ultrasound RF Signals for Joint Assessment of Breast Masses and Axillary Lymph Nodes Status.

  Ultrasound Med Biol, Jul 2026

• Establishing a Multimodal Model for Predicting Lymphovascular Invasion in Breast Cancer Using Deep Transfer Learning Based on Ultrasound and Dynamic Contrast-Enhanced Magnetic Resonance Imaging.

  Oncol Res Treat, Jul 2026

• An intelligent MRI-based all-in-one diagnostic strategy for axillary lymph node status in breast cancer.

  Nat Commun, Jun 2026

• Assessing the performance of deep learning and hand-crafted radiomics models using MRI and ultrasound in predicting axillary lymph node status in breast cancer: a systematic review and meta-analysis.

  Eur Radiol, Jun 2026

• Deep learning model for noninvasive prediction of Ki-67 expression and prognostic stratification in breast cancer: a multicenter retrospective study.

  Eur Radiol, May 2026

• Accuracy of Deep Learning for Detecting Axillary Lymph Node Metastasis in Breast Cancer: Systematic Review and Meta-Analysis.

  J Med Internet Res, Apr 2026

See which targets of this disease your abstract mentions, and go to the people working on them.